Global siRNA Drug Market Report, History and Forecast 2023-2029
The global market for siRNA Drug estimated was at US$ 1,596.51 million in the year 2023, is projected to reach a revised size of US$ 12,892.37 million by 2030, growing at a CAGR of 31.94% during the forecast period 2024-2030.
United States market for siRNA Drug was valued at $ 902.04 million in 2023 and will reach $ 5,220.55 million by 2030, at a CAGR of 25.58% during the forecast period of 2024 through 2030.
Europe market for siRNA Drug was valued at $ 505.85 million in 2023 and will reach $ 4,540.73 million by 2030, at a CAGR of 34.51 % during the forecast period of 2024 through 2030.
Rest of World market for siRNA Drug was valued at $ 188.62 million in 2023 and will reach $ 3,131.09 million by 2030, at a CAGR of 44.32 % during the forecast period of 2024 through 2030.
This report aims to provide a comprehensive presentation of the global market for siRNA Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding siRNA Drug.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global siRNA Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
Market Segmentation
This report covers the siRNA Drug segments by company, by Type, by Application, by region and country, and provides market size and CAGR for the history and forecast period (2019-2024, 2025-2030), considering 2023 as the base year. It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
By Company
Alnylam
Novartis
Novo Nordisk
Genzyme
Arrowhead
Silence
Sylentis
Avidity Biosciences
Sirnaomics
Segment by Type
Intravenous Injection
Subcutaneous Injection
Segment by Application
Nervous System Therapy
Endocrine and Metabolic Therapy
Others
By Region
United States
Rest of World
Canada
Japan
Brazil
China
Australia
Europe
Germany
France
U.K.
Italy
Switzerland
Nordic Countries
Rest of Europe
Chapter Outline
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2019-2024, 2025-2030). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Details of FDA-Approved siRNA Drugs
Chapter Five: Detailed analysis of siRNA Drug companies’ competitive landscape, revenue, market share and ranking, etc.
Chapter Six, Seven and Eight: United States, Europe and rest of world revenue by country.
Chapter Nine: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Ten: Provides siRNA Drug Industry Chain, Key Raw Materials and Upstream Cost Analysis
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: About siRNA Drug Development History and Future Outlook
Chapter Thirteen: Research Finding/Conclusion